Return to homepagePandemic Pact

SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93020C00041-0-9999-1

Grant search

Key facts

  • Disease

    Unspecified

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $599,977

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    PAUL GUYRE

  • Research Location

    United States of America

  • Lead Research Institution

    CELDARA MEDICAL, LLC

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Vaccine design and administration

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

This contract is part of the NIAID Adjuvant Development program, which supports the preclinical development of novel vaccine adjuvant candidates. The goal of this contract is to support the further development of the ASP-1 adjuvant within the context of a vaccine to protect against influenzas.